M&A / Deals AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid Pharmaceutical TechnologyAbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.M&A / DealsPain & AnaesthesiaRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries. M&A / DealsPain & AnaesthesiaRead full story Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: AbbVie enters world of pain in up to $715M deal with China’s Haisco Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026